ClinicalTrials.gg
Status unknownNCT05480592Updated Mar 9, 2023

A Study of HS-10380 in Chinese Participants

A Phase 1 interventional study of HS-10380 and Placebo in Schizophrenia, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-09.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 250 studies in Schizophrenia with a site in China — 62 open to participants now, 66 under way, 4 of them phase 3. Schizophrenia · China.

Planned enrollment
138th of 215
76 · median 100
Started
2022
with 16 others
Phase 1
22 of 250
7 open now
Registered
156th of 250
by date
Lead sponsor
6 of 250
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Among the 250 studies in Schizophrenia with a site in China, this one is the 138th largest by planned enrollment of the 215 interventional ones that give a count, is one of 17 that started in 2022, is one of 22 in phase 1, and was the 156th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

62 of the 250 studies in Schizophrenia with a site in China are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 250 studies in Schizophrenia with a site in China, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the safety and tolerability of single and multiple oral administered doses of HS-10380 in Chinese healthy subjects.

Read the detailed description

This is a phase I, randomized, double-blinded, placebo-controlled, both single ascending doses (SAD) study and multiple ascending dose (MAD) clinical trial to assess the safety, tolerability, and pharmacokinetics of HS-10380 in Chinese healthy subjects.

There will be four phases in SAD and MAD study: a 2-week screening phase, a 1-day baseline phase, a double-blind treatment phase, and a 1-week post-treatment (follow-up) phase.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • HS-10380
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subject aged from 18 to 45 years;
  2. Subject has a (BMI) between 18.5 and 26.0 kg/m2 at screening and the weight of male subjects is not less than 50 kg, and the weight of female subjects is not less than 45 kg;
  3. Voluntary subject who signs the form after understanding the purpose, content, process and possible risks of the trial;
  4. Subject is able to communicate well with the investigator and comply with the lifestyle constraints specified in the protocol, and cooperate to complete the trial procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subject has history or presence of disease or dysfunction affecting the clinical trial, including but not limited to neuropsychiatric system, cardiovascular system, urinary system, digestive system, respiratory system, musculoskeletal system, metabolic endocrine system, skin disease, blood system disease, immune system and tumor, etc.;
  2. Subject has any surgical condition or condition that may significantly affect the absorption, distribution, metabolism, and excretion of the drug, or any surgical condition or condition that may pose a hazard to the subjects participating in the trial, such as gastrointestinal surgery (gastrectomy, Gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, peptic ulcer, history of gastrointestinal bleeding, etc.;
  3. Subject has a history of significant drug allergies or known allergies to the components of the test drug;
  4. Subject has history or presence of psychiatric disorders and cerebral dysfunction, or subjects at risk of suicide according to the Columbia Suicide Severity Rating Scale (C-SSRS) or at risk of suicide according to the investigator's clinical judgment, or has a history of self-harm;
  5. Subject has a history of drug abuse within 1 year prior to screening, or has a positive urine drug result screen at screening;
  6. Subject has history of alcohol abuse or a single consumption of more than 14 units of alcohol (1 unit = 285 mL of beer, 25 mL of spirits, 150 mL of wine) in the nearly one year prior to screening or a positive breath test for alcohol at screening;
  7. Subject has smoked ≥5 cigarettes per day or consumed an average of ≥5 (200mL/cup) cups of coffee or tea per day in the 3 months before screening, or could not stop users during the study;
  8. Subject has special requirements for food or is unwilling to accept a uniform diet or has difficulty swallowing;
  9. Pregnant or breastfeeding women, or those who refuse to use effective (eg, abstinence, IUD) throughout the study period and 6 months after the end of the study, or those who have a sperm or egg donation plan;
  10. Subject has abnormal comprehensive physical examination, vital signs, laboratory tests, and 12-lead , which are judged by the investigator (eg: >450ms for men and >470ms for women, Friericia correction);
  11. Subject with resting pulse rate \<55 bpm or >100 bpm; systolic blood pressure \<90mmHg or >140mmHg; diastolic blood pressure \<60mmHg or >90mmHg at screening;
  12. Subject has detectable surface antigen (HBsAg), anti- virus (HCV), or (HIV) antibody at screening;
  13. Subject with (ALT), creatinine (Cr), blood urea nitrogen (BUN) exceeding the or serum prolactin greater than 2 times the upper limit of normal at the time of screening;
  14. Subject has donated blood or lost blood ≥ 400ml within 3 months before screening, or donated blood or lost blood ≥ 200ml within one month, or has a history of using blood products;
  15. Subject with a history of surgery within 3 months prior to screening, or who have not recovered from surgery, or who have anticipated surgery plans during the trial;
  16. Subject has taken any medication within 2 weeks (or 5 half-lives, whichever is longer) prior to screening or takes any medication throughout study, including prescription and over-the-counter medications, Chinese herbal medicines, and any drugs that inhibit or induce liver drug metabolizing enzymes (such as inducers and/or inhibitors of , CYP2D6 and CYP3A5);
  17. Subject has participated in any clinical trial or took any clinical trial drugs within 3 months before screening;
  18. Subject has dieted or received dietary therapy, or had significant changes in dietary habits within 30 days prior to screening;
  19. Subject has a history of vaccination within 30 days prior to screening, or has a vaccination schedule throughout the study;
  20. Subject with poor compliance or other problems which the investigator considers unsuitable for subject to participate.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Single Ascending Dose (SAD)

    Subjects in cohorts 1-6 will receive oral administration of single dose of HS-10380 tablets or matching placebo.

    Drug: HS-10380 · Drug: Placebo

  • Placebo comparator
    Multiple Ascending Dose (MAD)

    Subjects in cohorts 7 will receive oral administration of 7 dose of HS-10380 tablets or matching placebo.

    Drug: HS-10380 · Drug: Placebo

Interventions

  • Administered orally as a tablet

  • DrugPlacebo

    Administered orally as a tablet

06

What researchers measure

Primary outcomes

  1. Number of Subjects Experiencing Adverse Events (AEs)

    AE include adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Baseline to end of follow-up (a maximum of 20 days)

  2. Changes from baseline in laboratory tests

    Laboratory tests include blood routine, urine routine, blood biochemistry, coagulation function, thyroid function and serum prolactin;

    Time frame: Baseline to end of follow-up (a maximum of 20 days)

  3. Changes from baseline in vital signs

    Vital signs include respiration, pulse, blood pressure, body temperature and SpO2

    Time frame: Baseline to end of follow-up (a maximum of 20 days)

  4. Change from baseline in Electrocardiogram (ECG)

    ECG parameters including heart rate, PR interval, RR interval and QTcF, etc.

    Time frame: Baseline to end of follow-up (a maximum of 20 days)

  5. Change from baseline in weight (kg)

    Time frame: Baseline to end of follow-up (a maximum of 20 days)

  6. Change from baseline in physical examination

    Including general condition, heart, chest and abdomen, skin and mucous membranes, lymph node examination, etc.

    Time frame: Baseline to end of follow-up (a maximum of 20 days)

  7. Change from baseline in Simpson-Angus Scale (SAS) score

    The SAS is a 10-item testing instrument used to evaluate drug-related extrapyramidal syndromes. The following items are included in the SAS: gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella reflex, tremor, and salivation. Total score ranges from 0 to 40 with a higher score indicating increased severity.

    Time frame: Baseline to end of follow-up (a maximum of 20 days)

  8. Change from baseline in Abnormal Involuntary Movement Scale (AIMS) score

    AIMS is a rating scale measuring involuntary movements known as tardive dyskinesia, that sometimes develop as a side effect of long-term treatment with antipsychotic medications. The AIMS score was calculated as the sum of questions 1 through 7 of the AIMS instrument, which includes assessments of involuntary movements in the face, lips, jaw, tongue, upper and lower extremities, and neck/shoulders/hips. Each item is rated on a five-point scale of severity from 0-4 with 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Total scores range from 0 to 28.

    Time frame: Baseline to end of follow-up (a maximum of 20 days)

  9. Change from baseline in Barnes Akathisia Rating Scale (BARS) score

    BAS is a rating scale that is administered by physicians to assess the severity of drug-induced akathisia, which is a movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion, as well as by actions such as rocking while standing or sitting, lifting the feet as if marching on the spot, and crossing and uncrossing the legs while sitting. The following subcategories are scored: objective akathisia, subjective awareness of restlessness and subjective distress related to restlessness and are rated on a 4-point scale from 0-3. In addition, the global clinical assessment of akathisia uses a 6-point scale ranging from 0-5. Total score ranges from 0 to 14 with a higher score indicating increased severity.

    Time frame: Baseline to end of follow-up (a maximum of 20 days)

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of single-dose HS-10380 administration

    Time frame: Up to 120 hours post-dose

  2. Time of the Maximum Concentration (Tmax) of single-dose HS-10380 administration

    Time frame: Up to 120 hours post-dose

  3. Terminal rate constant (λz) of single-dose HS-10380 administration

    Time frame: Up to 120 hours post-dose

  4. Elimination half-life (t1/2) of single-dose HS-10380 administration

    Time frame: Up to 120 hours post-dose

  5. Area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC0-t) of single-dose HS-10380 administration

    Time frame: Up to 120 hours post-dose

  6. Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC0-∞) of single-dose HS-10380 administration

    Time frame: Up to 120 hours post-dose

  7. Apparent clearance (CL/F) of single-dose HS-10380 administration

    Time frame: Up to 120 hours post-dose

  8. Apparent volume of distribution (Vd/F) of single-dose HS-10380 administration

    Time frame: Up to 120 hours post-dose

  9. Mean retention time (MRT) of single-dose HS-10380 administration

    Time frame: Up to 120 hours post-dose

  10. Maximum plasma concentration (Cmax) of first HS-10380 administration

    Time frame: Up to 12 days

  11. Time of the Maximum Concentration (Tmax) of first HS-10380 administration

    Time frame: Up to 12 days

  12. Area under the plasma concentration-time curve from time zero to 24 hours (AUC0-24) first HS-10380 administration

    Time frame: Up to 24 hours

  13. Maximum concentration at steady state (Css, max) of multiple-dose HS-10380 administration

    Time frame: Up to 12 days

  14. Time of the maximum concentration at steady state (Tss, max) of multiple-dose HS-10380 administration

    Time frame: Up to 12 days

  15. Minimum concentration at steady state (Css, min) of multiple-dose HS-10380 administration

    Time frame: Up to 12 days

  16. Area under the concentration-time curve at steady state (AUCss) of multiple-dose HS-10380 administration

    Time frame: Up to 12 days

  17. Accumulation ratio (RAC) after multiple doses

    Time frame: Up to 12 days

07

Study locations

1 of 1 sites recruiting
  • Shanghai Mental Health Center
    Shanghai, Shanghai 200030, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Jun 2023, 10 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 10 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2022
First posted
Jul 29, 2022
StartActual
Aug 1, 2022
Primary completionEst.
Jun 30, 2023
CompletionEst.
Jul 30, 2023
Last update
Mar 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05480592
Responsible party
Sponsor
First posted
Jul 29, 2022
Start date
Aug 1, 2022
Primary completion
Jun 30, 2023 (estimated)
Completion
Jul 30, 2023 (estimated)
Last update
Mar 9, 2023

Study contacts

Huafang Li, MD
Contact
lhlh_5@163.com
021-34773128

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10380

Start the discussion